Biogen (BIIB) Free Cash Flow (2009 - 2026)

Biogen (BIIB) has reported Free Cash Flow for 18 consecutive years, with $594.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 167.46% year-over-year to $594.3 million; the TTM figure through Mar 2026 stood at $2.4 billion (down 0.57% YoY), while the FY2025 annual figure was $2.1 billion, down 24.65% from the prior year.
• Free Cash Flow came in at $594.3 million for Q1 2026 at Biogen, up from $468.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.2 billion in Q3 2025, with the low at -$261.4 million in Q4 2022.
• Average Free Cash Flow over 5 years is $457.7 million, with a median of $507.3 million recorded in 2024.
• Across the five-year window, Free Cash Flow plunged 133.23% in 2022 and jumped 1469.26% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$261.4 million in 2022, then jumped by 79.84% to -$52.7 million in 2023, then surged by 1469.26% to $721.6 million in 2024, then tumbled by 35.14% to $468.0 million in 2025, then grew by 26.99% to $594.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $594.3 million, $468.0 million, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.